Georgetown University Medical Center (GUMC) seminar highlighted research on a revolutionary approach to cancer treatment: ...

The newly issued patent covers a series of selective HDAC inhibitors designed to modulate the expression of genes involved in cancer progression, immune responses, and other critical biological ...

Michelle C. Werner agonized over whether the gene therapy treatment Elevidys was right for her teenage son. But to him, the ...

Mammalian genomes encode eleven proteins of the classical histone deacetylase (HDAC) family. They are numbered HDAC1 to HDAC11 and can be classified into four distinct groups (class I, IIa ...

Researchers at the University of Alabama at Birmingham discovered that combining regorafenib with a dual JAK/HDAC inhibitor ...

The patent covers selective histone deacetylase (HDAC) inhibitors designed to regulate genes involved in cancer progression, immune responses, and other biological processes. These inhibitors are ...

High mortality has been ... How Drugs Can Target the Thick 'Scar Tissue' of Pancreatic Cancer Dec. 6, 2023 — Researchers discovered how anti-cancer drugs called HDAC inhibitors help treat ...

As more drugs approach late-stage development for PAH, Cereno Scientific’s CEO expects more successful disease-modifying ...

必贝特第一第二大股东均系美国国籍，多名股东同在康盛生物；尚未实现产品的商业化生产和销售，尚未盈利且持续亏损；对BEBT-908存在较大依赖，未来商业化不确定；员工数量较少，独董之一任职数5家；两次股份支付近3.5亿元。